

Special Issue

Free or Nanoformulated Forms of Novel Protease Inhibitors for Cancer Therapy

Message from the Guest Editor

Many studies indicate that intracellular proteases often participate in tumor growth and progression, being involved in important biological processes such as immune and inflammatory responses, angiogenesis, proliferation, epithelial-to-mesenchymal transition (EMT) and many others. Among the anticancer strategies, the antagonization of protease activity with increasingly effective molecules is certainly an encouraging therapeutic approach, especially if formulated in nanoparticle-based delivery systems that can increase bioavailability and circulation time and allow for accumulation—specifically in tumor tissues. This Special Issue aims to establish a collection of papers to provide cutting-edge insight into all interested in this area of research. We welcome papers in the form of full research papers or focused reviews on some aspects of the theme. I look forward to receiving your contributions.

Guest Editor

Dr. Maria Francesca Armentano

Department of Scienze, University of Basilicata, Viale dell'Ateneo
Lucano 10, 85100 Potenza, Italy

Deadline for manuscript submissions

closed (20 January 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/133059

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).